KPTI

Karyopharm Therapeutics Inc.

0.86 USD

Last updated Dec 8, 06:15 UTC

Yesterday HIGH

$0.89

Yesterday LOW

$0.83

52w HIGH

$5.42

52w LOW

$0.67

EPS

-0.3

PE

-2.88

Next Earnings

Feb 14, 2024

Overview News Insider Transactions Government Trades

Karyopharm Therapeutics Inc. stock is up 15.11% since 30 days ago. The next earnings date is Feb 14, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 36.36% of the previous 10 December’s closed higher than November.

Karyopharm Therapeutics Inc. discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Wilmington, United States Of America

Website

karyopharm.com

Happy Mohamed

Wed Aug 2, 2023

Karyopharm Therapeutics Q2 EPS $(0.29) Beats $(0.34) Estimate, Sales $37.58M Beat $36.23M Estimate

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.34) by 14.71 percent. This is a 53.23 percent increase over losses of $(0.62) per
Vandana Singh

Wed Jul 26, 2023

Karyopharm's Selinexor Shows Progression-Free Survival of 27.4 Months In Endometrial Cancer With Certain Mutation

Karyopharm Therapeutics Inc (NASDAQ: KPTI) announced the presentation of updated exploratory subgroup analyses from the SIENDO study in patients with advanced or recurrent TP53 wild-type endometrial cancer at the virtual American Society of Clinical
richadhand@benzinga.com

Wed Jul 26, 2023

Wedbush Maintains Neutral on Karyopharm Therapeutics, Lowers Price Target to $4

Wedbush analyst David Nierengarten maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Neutral and lowers the price target from $7 to $4.
richadhand@benzinga.com

Wed Jul 26, 2023

HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and maintains $10 price target.
Benzinga Newsdesk

Wed Jul 26, 2023

Late Tuesday, Karyopharm Announced Presentation Of Updated Exploratory Subgroup Analyses From SIENDO Study Of Selinexor For Advanced Or Recurrent TP53 Wild-type Endometrial Cancer At Virtual American Society Of Clinical Oncology Plenary Series
Benzinga Newsdesk

Wed Jul 19, 2023

Karyopharm Announces Updated Exploratory Subgroup Analysis From SIENDO Study In Patients With Advanced Or Recurrent TP53 Wild-Type Endometrial Cancer To Be Presented At ASCO Plenary Series On July 25th

- Data Provide Further Support for Company's Ongoing Phase 3 Study Evaluating Selinexor as Maintenance Therapy Following Systemic Therapy in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer -
Benzinga Insights

Tue Jul 18, 2023

Stocks That Hit 52-Week Lows On Tuesday

During Tuesday's trading, 46 companies set new 52-week lows.
Vandana Singh

Tue Jul 18, 2023

Why Are Karyopharm Therapeutics Shares Gaining Today?

Karyopharm Therapeutics Inc (NASDAQ: KPTI) shares are trading higher after the FDA granted Fast Track Designation to the development program of selinexor for myelofibrosis, including primary myelofibrosis, post-essential thrombocythemia myelofibrosis, and post-
Benzinga Insights

Tue Jul 18, 2023

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Lisa Levin

Tue Jul 18, 2023

Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket

Gainers Biophytis S.A. (NASDAQ: BPTS) shares surged 53.9% to $3.31 in pre-market trading after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company's main product.